"dr Grażyna Pulka - alergolog, internista"

During the past decade, Grażyna Pulka Specjalistyczny Ośrodek, "ALL-MED" conducted 9 clinical trials. In the 10-year time frame, 9 clinical trials started and 6 clinical trials were completed, i.e. on average, 66.7% percent of trials that started reached the finish line to date. In the past 5 years, 3 clinical trials started and 5 clinical trials were completed. i.e. 166.7% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Grażyna Pulka Specjalistyczny Ośrodek, "ALL-MED"" #1 sponsor was "Eli Lilly and Company" with 2 trials, followed by "Fresenius Kabi SwissBioSim GmbH" with 2 trials sponsored, "Coherus Biosciences, Inc." with 1 trials sponsored, "Daiichi Sankyo, Inc." with 1 trials sponsored and "EMD Serono Research & Development Institute, Inc." with 1 trials sponsored. Other sponsors include -2 different institutions and companies that sponsored additional 8 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Grażyna Pulka Specjalistyczny Ośrodek, "ALL-MED"" #1 collaborator was "Dermira, Inc." with 2 trials as a collaborator, "Merck KGaA, Darmstadt, Germany" with 2 trials as a collaborator and "Quintiles, Inc." with 1 trials as a collaborator. Other collaborators include -3 different institutions and companies that were collaborators in the rest 3 trials.

According to Clinical.Site data, the most researched conditions in "Grażyna Pulka Specjalistyczny Ośrodek, "ALL-MED"" are "Atopic Dermatitis" (2 trials), "Psoriasis" (2 trials), "Rheumatoid Arthritis" (2 trials), "Asthma" (1 trials) and "Atrial Fibrillation" (1 trials). Many other conditions were trialed in "Grażyna Pulka Specjalistyczny Ośrodek, "ALL-MED"" in a lesser frequency.

Most popular intervention types in "Grażyna Pulka Specjalistyczny Ośrodek, "ALL-MED"" are "Drug" (7 trials) and "Biological" (3 trials). Other intervention types were less common.

The name of intervention was led by "Lebrikizumab" (3 trials), "Placebo" (2 trials), "Adalimumab" (1 trials), "CHS-1420" (1 trials) and "EU-approved RoActemra" (1 trials). Other intervention names were less common.

The vast majority of trials in "Grażyna Pulka Specjalistyczny Ośrodek, "ALL-MED"" are 10 trials for "All" genders.

Currently, there are NaN active trials in "Grażyna Pulka Specjalistyczny Ośrodek, "ALL-MED"". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 9 completed trials in Grażyna Pulka Specjalistyczny Ośrodek, "ALL-MED", undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Grażyna Pulka Specjalistyczny Ośrodek, "ALL-MED", 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 8 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".